G1 Therapeutics To Participate In The 23Rd Annual Needham Virtual Healthcare Conference


(MENAFN- GlobeNewsWire - Nasdaq) RESEARCH TRIANGLE PARK, N.C., April 04, 2024 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that G1's Chief Executive Officer Jack Bailey will provide a corporate presentation during the 23rd Annual Needham Virtual Healthcare Conference on Thursday, April 11, 2024, at 8:45 AM ET.

The webcast of the event will be accessible on the Events & Presentations page of .

About G1 Therapeutics
G1 Therapeutics, Inc. is a commercial-stage oncology biopharmaceutical company whose mission is to develop and deliver next-generation therapies that improve the lives of those affected by cancer, including the Company's first commercial product, COSELA® (trilaciclib). The Company is also evaluating therapies in combination with cytotoxic therapies and/or immunotherapy in areas of high unmet need including triple-negative breast cancer and extensive stage small cell lung cancer. G1's goal is to provide innovative therapeutic advances for people living with cancer. G1 is based in Research Triangle Park, N.C. For additional information, please visit and follow us on X (formerly known as Twitter) @G1Therapeutics and LinkedIn .

G1 Therapeutics ® and the G1 Therapeutics logo and COSELA ® and the COSELA logo are trademarks of G1 Therapeutics, Inc.

Contact:
Will Roberts
Communications Officer
Vice President, Investor Relations & Corporate Communications
(919) 907-1944
...


MENAFN04042024004107003653ID1108059619


Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.